Study of Stem Cell Transplant for Leukemia and Myelodysplastic Syndromes Using Clofarabine and Busulfan Regimen

Inclusion Criteria

• •Disease Criteria:
• •Acute myelogenous leukemia (AML)
• •Acute lymphocytic leukemia (ALL)
• •Myelodysplastic syndromes (MDS) Refractory anemia (RA) with adverse cytogenetics (SWOG criteria) or beyond (RAEB, RAEB-T, AML)
• •Other Myeloproliferative Disorders Myelofibrosis, Agnogenic Myeloid Metaplasia, Chronic Myelomonocytic Leukemia (CMML)
• •Chronic lymphocytic leukemia (CLL) High risk or advanced disease
• •18 years of age or older
• •Related or unrelated donor with HLA criteria as follows:
• •* Related donors: a serologic equivalent HLA Class I (A, B, and C) and Class II DRB1 or DQB1 matched donor OR a donor who is a single 1 antigen mismatched for A, B, C, DRB1, or DQB1 loci
• •* Unrelated donors: sequence-based typing fully matched A, B, C, DRB1, and DQB1 allele-matched donor OR a donor who is no greater than 1 antigen mismatched for A, B, C, DRB1, or DQB1 loci
• •Able to provide valid informed consent.
• •Female patients must have a negative serum pregnancy test within 2 weeks prior to enrollment.
• •Male and female patients must use an effective contraceptive method during the study and for up to 12 months after study treatment.